<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[14, 21] children and adolescents with autistic disorder.<br>[47, 54] children and adolescents with autistic disorders.<br>[73, 82] patients (5-17 years of age,<br>[157, 173] Fifty-six (71%) out of 79 enrolled patients completed the OLE;<br></td>
<td width=33%>
[14, 21] children and adolescents with autistic disorder.<br>[47, 55] children and adolescents with autistic disorders.
<br>[73, 101] patients (5-17 years of age, who completed the previous fixed-dose, 6 week, double-blind [DB] phase)<br>[157, 173] Fifty-six (71%) out of 79 enrolled patients completed the OLE;<br></td>
<td width=33%>
[14, 22] children and adolescents with autistic disorder.

<br>[47, 55] children and adolescents with autistic disorders.
<br>[73, 101] patients (5-17 years of age, who completed the previous fixed-dose, 6 week, double-blind [DB] phase)<br>[157, 173] Fifty-six (71%) out of 79 enrolled patients completed the OLE;<br></td>
</tr>
